{"id":68436,"date":"2026-04-09T12:55:37","date_gmt":"2026-04-09T07:25:37","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=68436"},"modified":"2026-04-09T12:55:38","modified_gmt":"2026-04-09T07:25:38","slug":"why-is-sun-pharma-share-price-falling","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/why-is-sun-pharma-share-price-falling\/","title":{"rendered":"Why Is Sun Pharmaceutical Industries Share Price Falling? Key Reasons And Share Price Target"},"content":{"rendered":"<p>Sun Pharmaceutical Industries is trading at Rs 1,580, down -20% from its 52-week high of Rs 2,000. The sustained decline in the Sun Pharmaceutical Industries share price reflects a combination of company-specific headwinds, sector pressures, and the broader macro overhang from the US 26% reciprocal tariff. This article explains every key reason behind the Sun Pharmaceutical Industries share price falling and provides a structured share price target for 2026.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/why-is-sun-pharma-share-price-falling\/#About_Sun_Pharmaceutical_Industries\" title=\"About Sun Pharmaceutical Industries\">About Sun Pharmaceutical Industries<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/why-is-sun-pharma-share-price-falling\/#Why_Is_Sun_Pharmaceutical_Industries_Share_Price_Falling_Key_Reasons\" title=\"Why Is Sun Pharmaceutical Industries Share Price Falling? Key Reasons\">Why Is Sun Pharmaceutical Industries Share Price Falling? Key Reasons<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/why-is-sun-pharma-share-price-falling\/#1_US_Specialty_Business_Growth_Decelerating\" title=\"1. US Specialty Business Growth Decelerating\">1. US Specialty Business Growth Decelerating<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/why-is-sun-pharma-share-price-falling\/#2_Ilumya_and_Cequa_Revenue_Plateau\" title=\"2. Ilumya and Cequa Revenue Plateau\">2. Ilumya and Cequa Revenue Plateau<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/why-is-sun-pharma-share-price-falling\/#3_India_Field_Force_Restructuring_Cost_Inflation\" title=\"3. India Field Force Restructuring Cost Inflation\">3. India Field Force Restructuring Cost Inflation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/why-is-sun-pharma-share-price-falling\/#4_Forex_Headwinds_on_International_Markets\" title=\"4. Forex Headwinds on International Markets\">4. Forex Headwinds on International Markets<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/why-is-sun-pharma-share-price-falling\/#5_Premium_Valuation_Relative_to_Indian_Pharma_Peers\" title=\"5. Premium Valuation Relative to Indian Pharma Peers\">5. Premium Valuation Relative to Indian Pharma Peers<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/why-is-sun-pharma-share-price-falling\/#Sun_Pharmaceutical_Industries_Latest_News_That_Impacted_the_Stock\" title=\"Sun Pharmaceutical Industries Latest News That Impacted the Stock\">Sun Pharmaceutical Industries Latest News That Impacted the Stock<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/why-is-sun-pharma-share-price-falling\/#Financial_Performance_Analysis\" title=\"Financial Performance Analysis\">Financial Performance Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/why-is-sun-pharma-share-price-falling\/#Technical_Signals_What_the_Charts_Are_Saying\" title=\"Technical Signals: What the Charts Are Saying\">Technical Signals: What the Charts Are Saying<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/why-is-sun-pharma-share-price-falling\/#Market_Sentiment_Institutional_Positioning\" title=\"Market Sentiment &amp; Institutional Positioning\">Market Sentiment &amp; Institutional Positioning<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/why-is-sun-pharma-share-price-falling\/#Future_Outlook_Can_Sun_Pharmaceutical_Industries_Recover\" title=\"Future Outlook: Can Sun Pharmaceutical Industries Recover?\">Future Outlook: Can Sun Pharmaceutical Industries Recover?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/why-is-sun-pharma-share-price-falling\/#Sun_Pharmaceutical_Industries_Share_Price_Target\" title=\"Sun Pharmaceutical Industries Share Price Target\">Sun Pharmaceutical Industries Share Price Target<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/why-is-sun-pharma-share-price-falling\/#Short-Term_Target_3%E2%80%936_Months\" title=\"Short-Term Target (3\u20136 Months)\">Short-Term Target (3\u20136 Months)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/why-is-sun-pharma-share-price-falling\/#12-Month_Analyst_Target\" title=\"12-Month Analyst Target\">12-Month Analyst Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/why-is-sun-pharma-share-price-falling\/#Long-Term_Target_2027%E2%80%932028\" title=\"Long-Term Target (2027\u20132028)\">Long-Term Target (2027\u20132028)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/why-is-sun-pharma-share-price-falling\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/why-is-sun-pharma-share-price-falling\/#FAQs\" title=\"FAQs\">FAQs<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/why-is-sun-pharma-share-price-falling\/#Q1_Why_is_Sun_Pharma_share_price_falling\" title=\"Q1. Why is Sun Pharma share price falling?\">Q1. Why is Sun Pharma share price falling?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/why-is-sun-pharma-share-price-falling\/#Q2_What_is_Sun_Pharma_share_price_target_for_2026\" title=\"Q2. What is Sun Pharma share price target for 2026?\">Q2. What is Sun Pharma share price target for 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/why-is-sun-pharma-share-price-falling\/#Q3_What_is_Sun_Pharmas_US_specialty_business\" title=\"Q3. What is Sun Pharma&#8217;s US specialty business?\">Q3. What is Sun Pharma&#8217;s US specialty business?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/why-is-sun-pharma-share-price-falling\/#Q4_What_is_Ilumya_and_when_could_it_face_biosimilar_competition\" title=\"Q4. What is Ilumya and when could it face biosimilar competition?\">Q4. What is Ilumya and when could it face biosimilar competition?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/why-is-sun-pharma-share-price-falling\/#Q5_What_is_Sun_Pharmas_EBITDA_margin\" title=\"Q5. What is Sun Pharma&#8217;s EBITDA margin?\">Q5. What is Sun Pharma&#8217;s EBITDA margin?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/why-is-sun-pharma-share-price-falling\/#Q6_Who_is_the_promoter_of_Sun_Pharma\" title=\"Q6. Who is the promoter of Sun Pharma?\">Q6. Who is the promoter of Sun Pharma?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/why-is-sun-pharma-share-price-falling\/#Q7_Is_Sun_Pharma_a_good_long-term_investment\" title=\"Q7. Is Sun Pharma a good long-term investment?\">Q7. Is Sun Pharma a good long-term investment?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/why-is-sun-pharma-share-price-falling\/#Q8_What_is_Sun_Pharmas_GLP-1_pipeline\" title=\"Q8. What is Sun Pharma&#8217;s GLP-1 pipeline?\">Q8. What is Sun Pharma&#8217;s GLP-1 pipeline?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/why-is-sun-pharma-share-price-falling\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"About_Sun_Pharmaceutical_Industries\"><\/span><strong>About Sun Pharmaceutical Industries<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/user\/log-in\">Click Here \u2013 Get Free Investment Predictions<\/a><\/p><p>Sun Pharmaceutical Industries (NSE: SUNPHARMA) is a leading listed company in the Pharma sector with a market capitalisation of Rs 3,79,000 Cr. At approximately 38x P\/E and 6.8x price-to-book, the stock&#8217;s 52-week range spans from Rs 1,480 to Rs 2,000. The current CMP of Rs 1,580 sits in the lower quarter of that range.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Why_Is_Sun_Pharmaceutical_Industries_Share_Price_Falling_Key_Reasons\"><\/span><strong>Why Is Sun Pharmaceutical Industries Share Price Falling? Key Reasons<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/user\/log-in\">Tap to Access Best Research Pieces on Univest<\/a><\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"1_US_Specialty_Business_Growth_Decelerating\"><\/span><strong>1. US Specialty Business Growth Decelerating<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Sun Pharma&#8217;s branded US specialty business \u2014 anchored by Ilumya (psoriasis), Cequa (dry eye), and Odomzo (basal cell carcinoma) \u2014 has been the primary driver of valuation premium over Indian pharma peers. Revenue from this specialty business grew at 25-30% CAGR through FY22-FY25. In Q3 FY26, growth decelerated to approximately 15% CC \u2014 still strong, but below the 20-25% the market had embedded in its target price assumptions.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"2_Ilumya_and_Cequa_Revenue_Plateau\"><\/span><strong>2. Ilumya and Cequa Revenue Plateau<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Ilumya, Sun Pharma&#8217;s IL-23 inhibitor for psoriasis, faces biosimilar competition beginning in 2026-27 as the compound patent protection window shortens. Cequa, for dry eye, faces intensifying competition from Xiidra (Novartis) and emerging therapies. Revenue plateauing in these two flagship products \u2014 which together contribute approximately 40% of Sun Pharma&#8217;s US specialty revenue \u2014 is the key concern for specialty trajectory.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"3_India_Field_Force_Restructuring_Cost_Inflation\"><\/span><strong>3. India Field Force Restructuring Cost Inflation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Sun Pharma is restructuring its India pharma field force to improve productivity and reduce overlap between the branded generic and OTC businesses. This restructuring involves voluntary retirement schemes, territorial realignment, and product portfolio rationalisation \u2014 all of which carry one-time costs that compress Q4 FY26 and Q1 FY27 PAT margins.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"4_Forex_Headwinds_on_International_Markets\"><\/span><strong>4. Forex Headwinds on International Markets<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Sun Pharma&#8217;s international business (excluding the US) includes meaningful revenue from emerging markets \u2014 Russia, South Africa, Brazil, and the Middle East. Currency weakness in several of these markets reduces reported revenue and PAT in rupee terms even when underlying volumes are healthy.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Premium_Valuation_Relative_to_Indian_Pharma_Peers\"><\/span><strong>5. Premium Valuation Relative to Indian Pharma Peers<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>At 38x P\/E, Sun Pharma commands the highest valuation multiple among large-cap Indian pharma companies. This premium reflects the specialty US business quality, but at 38x with a decelerating specialty growth rate, any further slowdown triggers disproportionate de-rating.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Sun_Pharmaceutical_Industries_Latest_News_That_Impacted_the_Stock\"><\/span><strong>Sun Pharmaceutical Industries Latest News That Impacted the Stock<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><strong>Q3 FY26 results (February 2026): <\/strong>Revenue Rs 13,268 crore (+10% YoY), PAT Rs 2,839 crore (+8% YoY). US specialty revenue growth 15% CC \u2014 below 20% estimate.<\/p><p><strong>February 2026: <\/strong>Ilumya biosimilar approved by FDA for review \u2014 biosimilar entry possible by FY28.<\/p><p><strong>March 2026: <\/strong>India field force restructuring costs \u2014 Rs 200-250 crore one-time charge in Q4 FY26 expected.<\/p><p><strong>April 2026: <\/strong>Large-cap pharma FII selling. Sun Pharma tests 52-week low zone.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Financial_Performance_Analysis\"><\/span><strong>Financial Performance Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>The quarterly numbers below highlight the key metrics versus the year-ago quarter for Sun Pharmaceutical Industries.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Key Metric<\/strong><\/td><td><strong>Latest Quarter<\/strong><\/td><td><strong>Year-Ago Quarter<\/strong><\/td><td><strong>YoY Change<\/strong><\/td><\/tr><tr><td>Revenue<\/td><td>Rs 13,268 Cr<\/td><td>Rs 12,061 Cr<\/td><td>+10.0%<\/td><\/tr><tr><td>Net Profit<\/td><td>Rs 2,839 Cr<\/td><td>Rs 2,628 Cr<\/td><td>+8.0%<\/td><\/tr><tr><td>EBITDA Margin<\/td><td>27.8%<\/td><td>28.2%<\/td><td>-40 bps<\/td><\/tr><tr><td>US Specialty Rev<\/td><td>Rs 3,200 Cr<\/td><td>Rs 2,783 Cr<\/td><td>+15% CC<\/td><\/tr><\/tbody><\/table><\/figure><p>Track Sun Pharmaceutical Industries live financials on <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a><\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Technical_Signals_What_the_Charts_Are_Saying\"><\/span><strong>Technical Signals: What the Charts Are Saying<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Sun Pharma is at Rs 1,580, approaching its 52-week low of Rs 1,480. Below the 50 and 100-day moving averages. Support at Rs 1,480-1,520. Resistance at Rs 1,750-1,800.<\/p><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Sun Pharmaceutical Industries live.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Market_Sentiment_Institutional_Positioning\"><\/span><strong>Market Sentiment &amp; Institutional Positioning<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Promoter (Shanghvi family) holds 54.5%. FII at 21.8% \u2014 high by pharma sector standards. DII at 16.4%.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Future_Outlook_Can_Sun_Pharmaceutical_Industries_Recover\"><\/span><strong>Future Outlook: Can Sun Pharmaceutical Industries Recover?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Sun Pharma&#8217;s long-term story \u2014 building India&#8217;s first global specialty pharma company \u2014 remains compelling. The specialty pipeline (TildrakizumAb, GL0034 GLP-1, and SCD-044 atopic dermatitis) offers genuine upside over 3-5 years. Recovery catalysts: Ilumya not losing significant market share to biosimilars in FY27, new specialty launches contributing meaningfully, and India business returning to 12-14% growth. The contrarian view: specialty drug investing is high-risk and 38x P\/E provides limited cushion for any pipeline setback.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Sun_Pharmaceutical_Industries_Share_Price_Target\"><\/span><strong>Sun Pharmaceutical Industries Share Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/user\/log-in\">Subscribe to Univest Pro for Premium Stock Research and F&amp;O Setups<\/a><\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Short-Term_Target_3%E2%80%936_Months\"><\/span><strong>Short-Term Target (3\u20136 Months)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Short-term support and range: Rs 1,480-1,650. The stock may stay in this band while headwinds persist.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"12-Month_Analyst_Target\"><\/span><strong>12-Month Analyst Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The 12-month analyst consensus for Sun Pharmaceutical Industries is Rs 1,900-2,100, implying meaningful recovery potential from Rs 1,580.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Long-Term_Target_2027%E2%80%932028\"><\/span><strong>Long-Term Target (2027\u20132028)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>In a recovery scenario, the FY28 long-term target is Rs 2,500-2,800. Track live on <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Sun Pharmaceutical Industries share price falling -20% from Rs 2,000 reflects sector headwinds and company-specific pressures. The 12-month analyst consensus of Rs 1,900-2,100 implies recovery potential. Short-term support is Rs 1,480-1,650. For more analysis, visit<\/p><p><a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a><\/p><p><strong>Disclaimer: <\/strong>This article is for informational purposes only. Please conduct your own research and consult a SEBI-registered financial advisor before making any investment decisions.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q1_Why_is_Sun_Pharma_share_price_falling\"><\/span><strong>Q1. Why is Sun Pharma share price falling?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Sun Pharma&#8217;s share price is falling due to US specialty revenue growth decelerating from 25-30% to 15% CC in Q3 FY26, Ilumya facing biosimilar approval review, Cequa facing intensifying competition, India field force restructuring one-time costs, forex headwinds on emerging market revenues, and premium 38x P\/E vulnerable to any growth slowdown.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q2_What_is_Sun_Pharma_share_price_target_for_2026\"><\/span><strong>Q2. What is Sun Pharma share price target for 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The 12-month analyst consensus is Rs 1,900-2,100. MOFSL targets Rs 2,000, YES Securities targets Rs 2,100. Short-term support is Rs 1,480-1,520.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q3_What_is_Sun_Pharmas_US_specialty_business\"><\/span><strong>Q3. What is Sun Pharma&#8217;s US specialty business?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Sun Pharma&#8217;s US specialty business includes Ilumya (IL-23 inhibitor for psoriasis), Cequa (cyclosporine for dry eye), and Odomzo (sonidegib for basal cell carcinoma). This business is the primary driver of Sun Pharma&#8217;s valuation premium over Indian pharma peers.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q4_What_is_Ilumya_and_when_could_it_face_biosimilar_competition\"><\/span><strong>Q4. What is Ilumya and when could it face biosimilar competition?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Ilumya (tildrakizumab) is a biologic drug for plaque psoriasis. The compound patent protection expires in 2028, with biosimilar competition potentially entering the market in 2028-2029. The FDA approval of the biosimilar for review is an early-stage signal, not an immediate competitive threat.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q5_What_is_Sun_Pharmas_EBITDA_margin\"><\/span><strong>Q5. What is Sun Pharma&#8217;s EBITDA margin?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Sun Pharma reported EBITDA margin of 27.8% in Q3 FY26, slightly declining from 28.2% a year ago. The margin remains among the highest in Indian large-cap pharma.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q6_Who_is_the_promoter_of_Sun_Pharma\"><\/span><strong>Q6. Who is the promoter of Sun Pharma?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Dilip Shanghvi (founder and Managing Director) and his family hold 54.5% of Sun Pharma \u2014 a high and confident promoter stake that has been stable for years.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q7_Is_Sun_Pharma_a_good_long-term_investment\"><\/span><strong>Q7. Is Sun Pharma a good long-term investment?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Sun Pharma has the strongest specialty pharma pipeline among Indian companies, high promoter holding, and excellent EBITDA margins. At Rs 1,580, the valuation has corrected meaningfully from Rs 2,000. For investors with 3-year horizon, the risk-reward is more favourable than 12 months ago. Consult a SEBI-registered advisor.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q8_What_is_Sun_Pharmas_GLP-1_pipeline\"><\/span><strong>Q8. What is Sun Pharma&#8217;s GLP-1 pipeline?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Sun Pharma has GL0034, an oral GLP-1 receptor agonist for obesity and diabetes, in Phase 2 clinical trials. This represents the longest-dated but potentially most significant pipeline asset if Phase 2 data is positive.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/mphasis-q4-results-2026\">Mphasis Q4 Results 2026: Date, Revenue Estimates, Key Catalysts &amp; Share Price Target<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/mastek-q4-results-2026\">Mastek Q4 Results 2026: Date, Revenue Estimates, Key Catalysts &amp; Share Price Target<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/cyient-q4-results-2026\">Cyient Q4 Results 2026: Date, Revenue Estimates, Key Catalysts &amp; Share Price Target<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/kpit-technologies-q4-results-2026\">KPIT Technologies Q4 Results 2026: Date, Revenue Estimates, Key Catalysts &amp; Share Price Target<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/zensar-technologies-q4-results-2026\">Zensar Technologies Q4 Results 2026: Date, Revenue Estimates, Key Catalysts &amp; Share Price Target<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Sun Pharmaceutical Industries is trading at Rs 1,580, down -20% from its 52-week high of Rs 2,000. The sustained decline in the Sun Pharmaceutical Industries share price reflects a combination of company-specific headwinds, sector pressures, and the broader macro overhang from the US 26% reciprocal tariff. This article explains every key reason behind the Sun<\/p>\n","protected":false},"author":29,"featured_media":68439,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3818],"class_list":["post-68436","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-share-price-falling"],"metadata":{"_edit_lock":["1775719653:29"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"rank_math_primary_category":["842"],"rank_math_seo_score":["73"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"rank_math_title":["Why Is Sun Pharma Share Price Falling? Key Reasons 2026"],"rank_math_description":["Sun Pharma share price down 20% from Rs 2,000 high. US specialty business slowdown, Ilumya competition, India field force restructuring costs, and valuation correction. 2026."],"rank_math_focus_keyword":["Sun Pharma Share"],"_thumbnail_id":["68439"],"_edit_last":["29"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["7620"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09125035\/SUNPHARMA_falling.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/68436","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=68436"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/68436\/revisions"}],"predecessor-version":[{"id":68451,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/68436\/revisions\/68451"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/68439"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=68436"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=68436"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=68436"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}